Compare Stocks

→ Millionaire investor and Republican donor makes surprising election prediction (From InvestorPlace) (Ad)

Compare stocks and their fundamentals, performance, price, and technicals. Use this free stock comparison tool to evaluate companies based on their analyst ratings, book value, debt, dividend, MarketRank, news sentiment, price performance, profitability, and more. Enter up to ten stock symbols separated by a comma or space (ex. BAC, JPM, WFC, C, GS).

Comparative Price Performance Over Time

Compare Stocks - Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ELEV Elevation Oncology	$3.54 +7.9%	$4.34	$0.36 ▼ $5.89	$193.43M	1.52	2.37 million shs	160,016 shs

Metaverse Stocks And Why You Can't Ignore Them

Thinking about investing in Meta, Roblox, or Unity? Click the link to learn what streetwise investors need to know about the metaverse and public markets before making an investment.

Get This Free Report

Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ELEV Elevation Oncology	0.00%	-11.35%	-30.66%	+12.71%	-13.23%

Millionaire investor and Republican donor makes surprising election prediction (Ad)

Find out who Louis believes is going to win the election... And why that will launch a second boom in AI stocks

Click for his six specific AI stock in the crosshairs

MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
ELEV Elevation Oncology	2.1961 of 5 stars	3.5	2.0	0.0	0.0	2.0	2.5	0.6

Analyst Ratings

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ELEV Elevation Oncology	3.00	Buy	$7.25	104.80% Upside

Current Analyst Ratings

Latest ELEV Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
5/3/2024	ELEV Elevation Oncology	Wedbush Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform ➝ Outperform	$8.00
4/9/2024	ELEV Elevation Oncology	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$6.00
3/7/2024	ELEV Elevation Oncology	JMP Securities Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Market Outperform ➝ Market Outperform	$7.00
3/7/2024	ELEV Elevation Oncology	Wedbush Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Outperform ➝ Outperform	$5.00 ➝ $8.00
3/7/2024	ELEV Elevation Oncology	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$6.00
3/1/2024	ELEV Elevation Oncology	JMP Securities Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Outperform	$7.00
2/20/2024	ELEV Elevation Oncology	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$1.50 ➝ $6.00

(Data available from 5/13/2021 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ELEV Elevation Oncology	N/A	N/A	N/A	N/A	$1.29 per share	N/A

Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ELEV Elevation Oncology	-$45.70M	-$1.04	N/A	N/A	N/A	N/A	-59.35%	-38.54%	8/1/2024 (Estimated)

Latest ELEV Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue	Details
3/6/2024	Q4 2023	ELEV Elevation Oncology	-$0.21	-$0.19	+$0.02	-$0.19	N/A	N/A

Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
ELEV Elevation Oncology	N/A	N/A	N/A	N/A	N/A

Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ELEV Elevation Oncology	0.41	46.22	46.22

Ownership

Institutional Ownership

Company	Institutional Ownership
ELEV Elevation Oncology	83.70%

Insider Ownership

Company	Insider Ownership
ELEV Elevation Oncology	14.90%

Miscellaneous

Company	Employees	Shares Outstanding	Free Float	Optionable
ELEV Elevation Oncology	29	54.64 million	46.50 million	Optionable

ELEV Headlines

Source	Headline
	Investing in Elevation Oncology Inc (ELEV) Stock: Methodology bovnews.com - May 13 at 9:33 AM
	Elevation Oncology to Present at the Citizens JMP Life Sciences Conference prnewswire.com - May 7 at 7:30 AM
	Elevation Oncology (NASDAQ:ELEV) Stock Rating Reaffirmed by Wedbush americanbankingnews.com - May 5 at 5:12 AM
	Analysts Are Bullish on These Healthcare Stocks: Elevation Oncology (ELEV), Moderna (MRNA) markets.businessinsider.com - May 4 at 12:12 AM
	Elevation Oncology (NASDAQ:ELEV) Given "Outperform" Rating at Wedbush marketbeat.com - May 3 at 12:14 PM
	Hint Health Announces 8th Annual Hint Summit, the Leading DPC Innovation Conference markets.businessinsider.com - May 2 at 2:47 PM
	Elevation Oncology GAAP EPS of -$0.23 msn.com - May 2 at 2:47 PM
	Elevation Oncology Shares Swing to 5% Gain After Extending Cash Runway marketwatch.com - May 2 at 2:47 PM
	ELEV Stock Earnings: Elevation Oncology Misses EPS for Q1 2024 msn.com - May 2 at 2:47 PM
	Elevation Oncology Reports First Quarter 2024 Financial Results and Highlights Recent Business Achievements prnewswire.com - May 2 at 7:30 AM
	Cabozantinib promising for advanced adrenocortical carcinoma medicalxpress.com - April 30 at 9:56 AM
	Clariane: First Quarter 2024 Revenue finance.yahoo.com - April 26 at 8:32 AM
	Intravitreal dexamethasone for macular edema may increase Intraocular Pressure: Study medicaldialogues.in - April 26 at 8:32 AM
	Elevation Oncology: Continuing To Seek Footing As It Climbs (Rating Upgrade) seekingalpha.com - April 22 at 2:30 PM
	Elevation Oncology, Inc. (NASDAQ:ELEV) Short Interest Up 8.2% in March marketbeat.com - April 17 at 11:16 AM
	Does Fracking Cause Cancer? cancertherapyadvisor.com - April 12 at 12:15 PM
	AACR, Cancer Treatment and the Promise of Antibody-Drug Conjugates biospace.com - April 12 at 12:15 PM
	Biologic drug-device combination immunotherapy for metastatic prostate cancer patients msn.com - April 10 at 2:19 AM
	Promising Preclinical Data and Positive Phase 2 Results Bolster Buy Rating for Elevation Oncology markets.businessinsider.com - April 9 at 4:19 PM
	Elevation Oncology Presents Preclinical Proof-of-Concept Data for HER3-ADC Program at AACR Annual Meeting 2024 finance.yahoo.com - April 8 at 5:40 PM
	Culprit lesion PCI before diagnostic coronary angiography effectively reduces reperfusion time in STEMI patients: JAMA medicaldialogues.in - March 31 at 6:49 PM
	Design for proposed southern Utah reservoir is poor and poses risk to public safety, geophysicist says msn.com - March 28 at 6:23 PM
	Melanoma: All about the risks, symptoms, and common myths msn.com - March 28 at 6:23 PM
	Scott Evaluates Treatment Options for Hydroxyurea-Resistant Polycythemia Vera targetedonc.com - March 28 at 6:23 PM

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

3 Stocks Leading the U.S. Agriculture Comeback
April 26, 2024 10:10 AM
View 3 Stocks Leading the U.S. Agriculture Comeback
How to Use Put Debit Spreads to Profit From Falling Stocks
April 26, 2024 9:30 AM
View How to Use Put Debit Spreads to Profit From Falling Stocks
Stock market today: Alphabet and Microsoft help Wall Street clinch its best week in nearly 6 months
April 26, 2024 3:21 AM
View Stock market today: Alphabet and Microsoft help Wall Street clinch its best week in nearly 6 months
Seagate Technology Warns Cloud Demand is Heating Up
April 30, 2024 10:10 AM
View Seagate Technology Warns Cloud Demand is Heating Up
Pinterest Prospers From AI Boosting Shop-Ability and Relevance
May 7, 2024 12:07 PM
View Pinterest Prospers From AI Boosting Shop-Ability and Relevance

All Headlines

Company Descriptions

Elevation Oncology

NASDAQ:ELEV

Elevation Oncology, Inc., an oncology company, focuses on the discovery and development of cancer therapies to treat patients across a range of solid tumors with significant unmet medical needs. The company's lead candidate is EO-3021, an antibody-drug conjugate designed to target Claudin 18.2, a clinically validated molecular target. Its EO-3021 selectively delivers a cytotoxic payload directly to cancer cells expressing Claudin 18.2. Elevation Oncology, Inc. has a license agreement with CSPC Megalith Biopharmaceutical Co., Ltd. to develop and commercialize EO-3021. The company was formerly known as 14ner Oncology, Inc. and changed its name to Elevation Oncology, Inc. in February 2020. The company was incorporated in 2019 and is based in Boston, Massachusetts.

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial